Oncocross is innovating the drug development process through its unique AI approach.
Based on gene expression pattern analysis, our innovative AI platform identifies the optimal indications
of new drug candidates in the area of cancer, rare diseases, and intractable diseases.
Our high accuracy allows a rapid entry into clinical trial, thereby reducing the risk of clinical failure.
Oncocross’s AI-driven treatment makes sure that no patients are left behind.
Oncocross is developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world.
Unrivaled Database Quality
Our analysis is based on 100,000+ patients, 235,000+ drugs, 410+ diseases medically curated transcriptome data.
Maximize the Value of a New Drug
We maximize the value of a new drug by identifying additional indications.
Fast Entry into Clinical Trials
We shorten the development time by identifying candidate drugs for any given disease.
High Success Rate of Clinical Trials
We identify the optimal indications by analyzing drug and disease expression data.
Oncocross presents a new paradigm for
AI drug development
Join Oncocross’s innovation